生命科学资讯

Shanghai's Cascade gets $72M to pursue MASH, obesity and diabetes drugs

Nektar posts one-year eczema success; Pfizer ends malnutrition trial

CSL’s Paul McKenzie out, as Gordon Naylor named interim CEO

AstraZeneca’s obesity pill hits in Phase 2, key cancer trials pushed back

'Bat-sh*t crazy': Biopharma leaders unload on regulatory chaos

Hengrui, Kailera push obesity pill ahead on promising mid-stage China data

FDA rejects Regenxbio's Hunter syndrome gene therapy

With scant data, RFK Jr. credits Trump for higher European drug prices

QuantX raises $85M Series B from Lilly, Sanofi Ventures

Despite FDA’s crackdown, pharma is still spending millions on ads

Lilly joins in vivo CAR-T sprint with $2.4B Orna acquisition

Galux raises $29M Series B; CSL teams up with Memo

#ACTRIMS26: Roche’s MS drug fenebrutinib beats Ocrevus, cutting risk of disability progression by 12%

Takeda, Iambic sign multiyear R&D deal for AI drug discovery

Novo Nordisk sues Hims over Wegovy patent infringement, considers seeking 'hundreds of millions' in damages

Lilly returns to Innovent to partner on cancer and immune diseases

Hims says it will stop selling GLP-1 pill, after legal pressure from US

#ACTRIMS26: Sanofi unpacks data from a failed Phase 3 tolebrutinib trial in PPMS

The Hims vs. Novo showdown; Pfizer’s monthly GLP-1 data; Q4 earnings roundup; and more

US calls for DOJ investigation of Hims over GLP-1 drugs